FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

OMB APPROVAL									
OMB Number:	3235-0287								
Estimated average l	nurden								

hours per response:

0.5

	Check this box if no longer subject to
١	Section 16. Form 4 or Form 5
	obligations may continue. See
	Instruction 1(b).

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*  BAUM MARK L				2. Issuer Name <b>and</b> Ticker or Trading Symbol Imprimis Pharmaceuticals, Inc. [ IMMY ]								elationship o eck all applic X Director	able)	g Perso	on(s) to Issu 10% Ow Other (s	ner		
(Last) (First) (Middle) C/O IMPRIMIS PHARMACEUTICALS, INC. 12264 EL CAMINO REAL, SUITE 350					3. Date of Earliest Transaction (Month/Day/Year) 04/01/2016								X Officer (give title Other (specify below)  Chief Executive Officer					
(Street) SAN DIEGO CA 92130 (City) (State) (Zip)				4.	Line								ndividual or Joint/Group Filing (Check Applicable  X Form filed by One Reporting Person Form filed by More than One Reporting Person					
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																	
Date			ransaction e onth/Day/		2A. Deemed Execution Date, if any (Month/Day/Year		Transaction Dispose Code (Instr.		ities Acquired (A) o d Of (D) (Instr. 3, 4 a		Beneficia Owned F	s illy ollowing	Form (D) or	Form: Direct D) or Indirect I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership			
									v	Amount	(A) o (D)	r Price		ransaction(s) Instr. 3 and 4)		(	Instr. 4)	
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																		
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code (Instr.		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)		
				Code	v	(A)	(D)	Date Exercisable		kpiration ate	Title	Amount or Number of Shares		Transaction(s) (Instr. 4)				
Option - Right to Buy	\$3.95	04/01/2016		A		180,000		(1)	04	4/01/2026	Common Stock	180,000	\$0	180,0	00	D		

## **Explanation of Responses:**

1. Represents stock options granted under the Issuer's 2007 Stock Incentive and Awards Plan. The stock options vest in equal quarterly installments over a three year period.

/s/ Mark L. Baum

04/05/2016

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.